By adopting the latest lifestyles many of the people have become prey to several diseases like diabetes. But now people can protect themselves from these diseases by using the latest anti-diabetic drug and it seems that this drug sale is flourishing. This anti-diabetic molecule has for the first time become the largest-selling formulation in the domestic pharma retail market. This latest anti-diabetic drug is also one of the most prescribed too, and it is a combination of glimepiride and metformin and it has dethroned the popular class of anti-infective medicines, led by widely-used medicine brands like GSK‘s Augmentin (a combination of amoxycillin and clavulanic acid) in May reports TNN.
The therapy, which generated revenue of 103 crore in May, is the first diabetes treatment to become the top-selling medication in the country. Even the analysts tracking the market said the anti-infective therapy had always been ranked on top. The primary reason behind the flourishing sales for the anti-diabetic molecule is its faster growth, as well as the anti-infective molecule coming under price control. Sales of Gluconorm, which consists of the combination of metformin and glimepiride, grew by 34.4 percent last month, versus about 4 percent for Augmentin.
AIOCD AWACS vice president Hari Natarajan noted that anti-infective therapies lost values because of price control, while anti-diabetic therapy sales are growing at a faster rate. The anti-diabetes market in India is growing at a rate of 20 percent annually, with metformin and glimepiride combination therapies comprising one-fourth of the market. Over last few years the sales of diabetes molecule have been climbing up and have shown a steady increase month on month from 97 crore in December. According to doctors due to the affordability and effectiveness the anti-diabetes combination is widely used.
“While metformin is the best drug to treat diabetes, combination therapy with glimepiride is required in most cases sooner or later. In India, this combination is most commonly-used since it is cheap and effective. Because of unabated diabetes, increasing use of this combined therapy is understandable”, says Dr Anoop Misra, director of Delhi-based Fortis-CDOC hospital for diabetes.
The sales of Augmentin the anti-infective molecule by GSK have been declining month on month, from 116 crore in 2013 to 103 crore in May this year. According to a market player the growth of the anti-diabetic sub-group as against the other anti-diabetic medicines, could also be attributed to the negative news around widely-prescribed drug Pioglitazone which led to a huge fall in its sales. For the 12-month period ended May 2014, the combination of metformin and glimepiride generated Rs 1142 crore in sales, trailing the Rs 1329 crore amassed by the anti-infective combination of amoxycillin and clavulanic acid.